Arrowpoint Investment Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.06M Buy
2,548
+2,106
+476% +$2.15M 0.67% 27
2026
Q1
$407K Sell
442
-8,751
-95% -$8.87M 0.36% 48
2025
Q4
$9.88M Buy
+9,193
New +$8.79M 1.46% 15

Other funds holding LLY

Arrowpoint Investment Partners's LLY Position: Q2 2026 in Review

Arrowpoint Investment Partners increased its Eli Lilly (LLY) stake by 476% in Q2 2026, buying an estimated $2.15M and bringing the position to 2,548 shares worth $3.06M. The position accounts for 0.67% of the portfolio, ranked #27.

Arrowpoint Investment Partners first reported a position in LLY in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.88M in Q4 2025. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Arrowpoint Investment Partners held 2,548 shares of Eli Lilly worth $3.06M as of Q2 2026.
  • Arrowpoint Investment Partners bought 2,106 Eli Lilly shares in Q2 2026, an estimated $2.15M.
  • Eli Lilly made up 0.67% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #27 holding.
  • Arrowpoint Investment Partners first reported a position in Eli Lilly in Q4 2025 and has held it in 3 quarters since.
  • Arrowpoint Investment Partners's Eli Lilly position peaked at $9.88M in Q4 2025.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.